Floatz logo

Ropivacaine

Developmental Dysplasia Of The Hip

Explore 3 assets in Developmental Dysplasia Of The Hip →
Floatz Rating
BB68/100
Confidence
Indicative
v0.2
Sponsor
University of California, Los Angeles
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54Moderate confidence
Detailed axis rationale is planned and will be published soon.

No trial-level evidence is linked to this axis yet.

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Developmental Dysplasia Of The Hip

AssetSponsorPhaseRating
Ropivacaine (this asset)University of California, Los AngelesApprovedBB · 68
MarcaineUniversity of California, Los AngelesP4BB
LidocaineUniversity of California, Los AngelesP4BB

Other indications for Ropivacaine

IndicationSponsorPhaseRating
Osteoarthritis, Hip—P4BBB · 76
Post-Operative Pain, Non-Human Animal—P4BBB · 76
Cerebral Palsy—P4BB · 70

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Ropivacaine in Developmental Dysplasia Of The Hip. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/ropivacaine-developmental-dysplasia-of-the-hip

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →